股票简称：和元生物 股票代码：688238 2025 年第四次临时股东会 会议资料 和元生物技术（上海）股份有限公司 OBiO Technology (Shanghai) Corp., Ltd. 2025 年 11 月 和元生物技术（上海）股份有限公司 2025 年第四次临时股东会会议资料 和元生物技术（上海）股份有限公司 2025 年第四次临时股东会会议资料目录 | 2025 年第四次临时股东会会议须知 | 2 | | --- | --- | | 2025 年第四次临时股东会会议议程 | 4 | | 2025 年第四次临时股东会会议议案 | 6 | | 议案一、《关于补选第四届董事会非独立董事的议案》 7 | | | 议案二、《关于变更第四届董事会独立董事的议案》 8 | | 1 和元生物技术（上海）股份有限公司 2025 年第四次临时股东会会议资料 和元生物技术（上海）股份有限公司 2025 年第四次临时股东会会议须知 为维护广大投资者的合法权益，确保和元生物技术（上海）股份有限公司（以 下简称"公司"或"和元生物"）股东会的正常秩序和议事效率，保障股东在本 次股东会期间依法行使权利，根据《中华人民共和国 ...

股票简称：和元生物 股票代码：688238 2025 年第四次临时股东会 会议资料 和元生物技术（上海）股份有限公司 OBiO Technology (Shanghai) Corp., Ltd. 2025 年 11 月 和元生物技术（上海）股份有限公司 2025 年第四次临时股东会会议资料 和元生物技术（上海）股份有限公司 2025 年第四次临时股东会会议资料目录 | 2025 年第四次临时股东会会议须知 | | 2 | | --- | --- | --- | | 2025 年第四次临时股东会会议议程 | | 4 | | 2025 年第四次临时股东会会议议案 | | 6 | | 议案一、《关于补选第四届董事会非独立董事的议案》 | | 7 | | 议案二、《关于变更第四届董事会独立董事的议案》 | | 8 | 1 和元生物技术（上海）股份有限公司 2025 年第四次临时股东会会议资料 和元生物技术（上海）股份有限公司 2025 年第四次临时股东会会议须知 为维护广大投资者的合法权益，确保和元生物技术（上海）股份有限公司（以 下简称"公司"或"和元生物"）股东会的正常秩序和议事效率，保障股东在本 次股东会期间依 ...

Core Viewpoint - He Yuan Bio is a leading enterprise in the domestic gene therapy CRO/CDMO service sector, providing critical technical support for the gene therapy industry [1] Group 1: Business Overview - He Yuan Bio was established on March 5, 2013, and was listed on the Shanghai Stock Exchange on March 22, 2022 [1] - The company specializes in providing CRO services for basic research in gene therapy, including the development of gene therapy vectors and gene function research, as well as CDMO services for the development of gene drugs [1] Group 2: Financial Performance - For Q3 2025, He Yuan Bio reported revenue of 180 million yuan, ranking 28th among 29 companies in the industry, significantly lower than the industry leader WuXi AppTec's 32.857 billion yuan and second-place Kanglong Chemical's 10.086 billion yuan [2] - The net profit for the same period was -162 million yuan, placing the company at the bottom of the industry rankings, with the industry leader WuXi AppTec reporting a net profit of 12.206 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, He Yuan Bio's debt-to-asset ratio was 30.03%, higher than the previous year's 20.62% and above the industry average of 22.79% [3] - The gross profit margin for Q3 2025 was -16.75%, an improvement from -21.95% in the previous year but still significantly below the industry average of 37.70% [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 11.44% to 14,000, while the average number of circulating A-shares held per account decreased by 10.27% to 45,600 [5] - The company reported that its 1H25 performance met expectations, with revenue of 120 million yuan, a year-on-year increase of 6.01%, and a narrowed net loss of 105 million yuan compared to the previous year [5] Group 5: Management Compensation - The chairman and general manager, Pan Oudong, received a salary of 1.0594 million yuan in 2024, a slight decrease of 5,000 yuan from 2023 [4]

Core Insights - He Yuan Bio (688238.SH) released its Q3 2025 financial report on October 28, 2025, indicating a total of 73.72 million shares held by five institutional investors, accounting for 11.36% of the company's total share capital [1] - The institutional holding percentage decreased by 1.53 percentage points compared to the previous quarter [1] Institutional Investors - The five institutional investors include Shanghai Zhangjiang Technology Venture Capital Co., Ltd., Zhejiang Huarui Shengyin Venture Capital Co., Ltd., Shanghai Tanying Investment Partnership (Limited Partnership), Shanghai Zhangjiang Torch Venture Capital Co., Ltd., and Shanghai Ouli Investment Management Center (Limited Partnership) [1] - The total institutional holding percentage stands at 11.36% [1] Public Funds - In this period, 67 public funds were not disclosed compared to the previous quarter, including notable funds such as Huatai-PB CSI Precision Medical Index (LOF) A, SSE Composite Index ETF, Guotai SSE Comprehensive ETF, and others [1]

Core Viewpoint - He Yuan Bio reported stable revenue with a slight decrease in net loss for the first three quarters of 2025, indicating resilience in its business despite challenges in certain segments [1][2]. Financial Performance - For the first nine months of 2025, He Yuan Bio achieved revenue of 180 million yuan, remaining flat year-on-year; the net profit attributable to shareholders was -162 million yuan, a reduction in loss by 27.65 million yuan compared to the previous year [1]. - In Q3 2025, the company recorded revenue of 60.5 million yuan and a net profit of -57.5 million yuan [1]. Business Segments - The CRO business generated revenue of 61.99 million yuan, reflecting a growth of 2.81% year-on-year, indicating stable growth [1]. - The CDMO business saw a revenue decline of 9.72% to 96.70 million yuan, primarily due to variations in order types and project progress [1]. - Other main businesses, including research reagents and cell storage services, achieved revenue of 21.39 million yuan, up 55.99% year-on-year [1]. R&D and Technological Capabilities - He Yuan Bio has established a comprehensive technology and production system in the CGT field, with significant R&D capabilities across various platforms [2]. - The company invested 34.66 million yuan in R&D, accounting for 19.22% of its revenue, and has obtained a total of 60 IND approvals [2]. - The company has filed for multiple patents and trademarks, enhancing its intellectual property portfolio [2]. Market Position and Strategy - He Yuan Bio serves over 14,700 research laboratories and is expanding its market share through strategic marketing and academic collaborations [3]. - The company has secured over 120 million yuan in new CDMO orders and assisted clients in obtaining 16 IND approvals, showcasing its strong industry presence [3]. - The company is actively exploring new business avenues in regenerative medicine, including stem cells and immune cells [3]. Production Capacity - The Shanghai Lingang industrial base features 11 GMP vector production lines and 18 GMP cell production lines, positioning the company competitively on a global scale [4]. - The base has achieved full production capacity, with increasing utilization rates expected as client pipelines advance [4]. - He Yuan Bio aims to leverage its technological advancements and new business developments to strengthen its market leadership in the CGT sector [4].

Core Viewpoint - He Yuan Biological (688238.SH) reported a decline in total operating revenue for the first three quarters of 2025, alongside a significant reduction in net loss compared to the previous year [1] Financial Performance - Total operating revenue for the first three quarters of 2025 reached 180 million yuan, representing a year-on-year decrease of 1.91% [1] - The net profit attributable to shareholders of the parent company was -162 million yuan, which is a reduction in loss by 27.65 million yuan compared to the same period last year [1] - Basic earnings per share stood at -0.254 yuan [1]

Core Viewpoint - He Yuan Biotechnology (Shanghai) Co., Ltd. reported stable revenue with a slight reduction in net loss for the first three quarters of 2025, indicating resilience in a challenging market environment [1] Company Performance - For the first three quarters of 2025, He Yuan Biotechnology achieved operating revenue of 180 million yuan, remaining flat compared to the same period last year; net loss was 162 million yuan, a reduction of 27.65 million yuan year-on-year [1] - The company secured over 120 million yuan in new CDMO orders, assisting clients in obtaining 16 IND approvals in China and the U.S., including 2 from the FDA [1] - As of September 2025, the company has accumulated 60 IND approvals covering various advanced fields such as oncolytic viruses and AAV gene therapy, positioning it among the leaders in the domestic industry [1] Business Segments - In the first three quarters of 2025, the revenue from the cell and gene therapy CRO business was approximately 61.99 million yuan, a year-on-year increase of 2.81% [1] - Revenue from the cell and gene therapy CDMO business was approximately 96.70 million yuan, a decline of 9.72% year-on-year, influenced by the types of CDMO orders executed and the progress of different projects [1] - Other main business segments, including research reagents and cell storage services, generated revenue of approximately 21.39 million yuan, reflecting a significant growth of 55.99% year-on-year [1] Research and Development - He Yuan Biotechnology invested approximately 34.66 million yuan in R&D during the first three quarters of 2025, accounting for 19.22% of its operating revenue [2] - The company added 1 new invention patent and 6 domestic registered trademarks, along with multiple applications for new patents and trademarks [2] Production Capacity - The company has established 11 GMP vector production lines and 18 GMP cell production lines at its industrial base in Shanghai, with fermentation and cell culture capabilities ranging from 5L to 2000L [3] - The first phase of the industrial base is fully operational, and the capacity utilization rate is expected to increase as client pipelines and orders grow [3] - He Yuan Biotechnology has implemented an intelligent R&D system to enhance efficiency in vector screening and process development, providing comprehensive services from drug discovery to commercial production [3] Market Position and Strategy - The company serves over 14,700 research laboratories through its CRO business and is steadily advancing in overseas markets using targeted marketing strategies [3] - He Yuan Biotechnology is actively expanding into the regenerative medicine sector, exploring new business avenues such as stem cells and exosomes through joint laboratories and participation in standard-setting [3] Industry Outlook - The cell and gene therapy industry is still in a growth phase, as evidenced by the approval of several high-priced CAR-T therapies in the recent national insurance directory adjustments [4]

证券代码：688238 证券简称：和元生物 公告编号：2025-063 和元生物技术（上海）股份有限公司 关于召开 2025 年三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 14 日(星期五)至 11 月 20 日(星期四)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 zhengquanbu@obiosh.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 和元生物技术（上海）股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日披露公司《2025 年三季度报告》，为便于广大投资者更全面深入地了解 公司 2025 年三季度经营成果、财务状况，公司计划于 2025 年 11 月 21 日(星期 五)下午 14:00-15:00 举行 2025 年三季度业绩说明会，就投资者关心的问题进行 交流。 一、说明会类型 本次业绩说明会以网络 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-061 和元生物技术（上海）股份有限公司 关于公司董事辞职暨补选董事并调整董事会专门委 员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●和元生物技术（上海）股份有限公司（以下简称"公司"）董事会于近日 收到公司非独立董事王富杰先生提交的书面辞职报告。王富杰先生因个人身体健 康原因，经慎重考虑，申请辞去公司第四届董事会非独立董事职务，同时辞去第 四届董事会审计委员会委员职务。离任后，王富杰先生将不再担任公司任何职务。 ●公司董事会于近日收到公司独立董事吴丹枫女士提交的书面辞职报告。吴 丹枫女士因个人原因，申请辞去公司第四届董事会独立董事职务，同时辞去第四 届董事会审计委员会主任委员、薪酬与考核委员会委员职务。离任后，吴丹枫女 士将不再担任公司任何职务。 ●公司于 2025 年 10 月 24 日召开第四届董事会第四次会议，审议通过了《关 于补选第四届董事会非独立董事的议案》《关于变更第四届董事会独立董事的议 案》《关于调整第四届 ...

科创板上市公司独立董事候选人声明与承诺 本人计小青，已充分了解并同意由提名人和元生物技术（上海）股份有限公 司董事会提名为和元生物技术（上海）股份有限公司第四届董事会独立董事候选 人。本人公开声明，本人具备独立董事任职资格，保证不存在任何影响本人担任 和元生物技术（上海）股份有限公司独立董事独立性的关系，具体声明并承诺如 下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有五年以上法律、经济会计、财务、管理等履行独立董 事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （六）中共中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的 意见》的相关规定（如适用）； （七）中国人民银行《股份制商业银行独立董事和外部监事制度指引》等的 相关规定（如适用）； （八）中国证监会《证券基金经营机构董事、监事、高级管理人员及从业人 员监督管理办法》等的相关规定（如适用）； （九）《银行业金融机构董事（理事）和高级管理人员任职资格管理办法》 《保险公司董事、监事和高级管理人员任职资格管理规定》《保险机构独立董事 管理办法》等的相关规 ...